Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 312

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Plasma Aβ42/40 ratio, p‐tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross‐sectional and longitudinal study in the AIBL cohort

Open access
Chatterjee, Pratishtha, Pedrini, Steve, Doecke, James D., Thota, Rohith, Villemagne, Victor L., Doré, Vincent, Singh, Abhay K., Wang, Penghao, Rainey‐Smith, Stephanie, Fowler, Christopher, Taddei, Kevin, Sohrabi, Hamid R., Molloy, Mark P., Ames, David, Maruff, Paul, Rowe, Christopher C., Masters, Colin L., Martins, Ralph N., the AIBL Research Group·2023·Alzheimer's & Dementia

Abstract

Introduction: Plasma amyloid beta (Aβ)1‐42/Aβ1‐40 ratio, phosphorylated‐tau181 (p‐tau181), glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) are putative blood biomarkers for Alzheimer's disease (AD). However, head‐to‐head cross‐sectional and longitudinal comparisons of the aforementioned biomarkers across the AD continuum are lacking. Methods: Plasma Aβ1‐42, Aβ1‐40, p‐tau181, GFAP, and NfL were measured utilizing the Single Molecule Array (Simoa) platform and compared cross‐sectionally across the AD continuum, wherein Aβ‐PET (positron emission tomography)–negative cognitively unimpaired (CU Aβ−, n = 81) and mild cognitive impairment (MCI Aβ−, n = 26) participants were compared with Aβ‐PET–positive participants across the AD continuum (CU Aβ+, n = 39; MCI Aβ+, n = 33; AD Aβ+, n = 46) from the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL) cohort. Longitudinal plasma biomarker changes were also assessed in MCI (n = 27) and AD (n = 29) participants compared with CU (n = 120) participants. In addition, associations between baseline plasma biomarker levels and prospective cognitive decline and Aβ‐PET load were assessed over a 7 to 10‐year duration. Results: Lower plasma Aβ1‐42/Aβ1‐40 ratio and elevated p‐tau181 and GFAP were observed in CU Aβ+, MCI Aβ+, and AD Aβ+, whereas elevated plasma NfL was observed in MCI Aβ+ and AD Aβ+, compared with CU Aβ− and MCI Aβ−. Among the aforementioned plasma biomarkers, for models with and without AD risk factors (age, sex, and apolipoprotein E (APOE) ε4 carrier status), p‐tau181 performed equivalent to or better than other biomarkers in predicting a brain Aβ−/+ status across the AD continuum. However, for models with and without the AD risk factors, a biomarker panel of Aβ1‐42/Aβ1‐40, p‐tau181, and GFAP performed equivalent to or better than any of the biomarkers alone in predicting brain Aβ−/+ status across the AD continuum. Longitudinally, plasma Aβ1‐42/Aβ1‐40, p‐tau181, and GFAP were altered in MCI compared with CU, and plasma GFAP and NfL were altered in AD compared with CU. In addition, lower plasma Aβ1‐42/Aβ1‐40 and higher p‐tau181, GFAP, and NfL were associated with prospective cognitive decline and lower plasma Aβ1‐42/Aβ1‐40, and higher p‐tau181 and GFAP were associated with increased Aβ‐PET load prospectively. Discussion: These findings suggest that plasma biomarkers are altered cross‐sectionally and longitudinally, along the AD continuum, and are prospectively associated with cognitive decline and brain Aβ‐PET load. In addition, although p‐tau181 performed equivalent to or better than other biomarkers in predicting an Aβ−/+ status across the AD continuum, a panel of biomarkers may have superior Aβ−/+ status predictive capability across the AD continuum. HIGHLIGHTS: Area under the curve (AUC) of p‐tau181 ≥ AUC of Aβ42/40, GFAP, NfL in predicting PET Aβ−/+ status (Aβ−/+). AUC of Aβ42/40+p‐tau181+GFAP panel ≥ AUC of Aβ42/40/p‐tau181/GFAP/NfL for Aβ−/+. Longitudinally, Aβ42/40, p‐tau181, and GFAP were altered in MCI versus CU. Longitudinally, GFAP and NfL were altered in AD versus CU. Aβ42/40, p‐tau181, GFAP, and NfL are associated with prospective cognitive decline. Aβ42/40, p‐tau181, and GFAP are associated with increased PET Aβ load prospectively.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/alz.12724

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 57 references

Cited by

See all 312

Metadata

Authors
Chatterjee, P., Pedrini, S., Doecke, J. D., Thota, R., Villemagne, V. L., Doré, V., Singh, A. K., Wang, P., Rainey‐Smith, S., Fowler, C., Taddei, K., Sohrabi, H. R., Molloy, M. P., Ames, D., Maruff, P., Rowe, C. C., Masters, C. L., Martins, R. N., & the AIBL Research Group
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2022-07-21
Volume
19
Issue
4
Pages
1117-1134
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
OpenAlex
W4286110976
Cited by
312
References
57
FWCI
32.29
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Plasma Aβ42/40 ratio, p‐tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross‐sectional and longitudinal study in the AIBL cohort. https://app.cochat.ai/papers/10.1002/alz.12724
The paper
Chatterjee, P., Pedrini, S., Doecke, J. D., Thota, R., Villemagne, V. L., Doré, V., Singh, A. K., Wang, P., Rainey‐Smith, S., Fowler, C., Taddei, K., Sohrabi, H. R., Molloy, M. P., Ames, D., Maruff, P., Rowe, C. C., Masters, C. L., Martins, R. N., & the AIBL Research Group. (2023). Plasma Aβ42/40 ratio, p‐tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross‐sectional and longitudinal study in the AIBL cohort. Alzheimer's & Dementia. https://doi.org/10.1002/alz.12724

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.